JCB Laboratories, LLC, Wichita, KS

Is JCB Laboratories, LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “Out of business”.

Does JCB Laboratories, LLC hold a Kansas pharmacy license?

State board of pharmacy records for Kansas are not checked: the board’s website answers automated requests with a bot challenge, and this index does not work around blocks. The Colorado State Board of Pharmacy also lists nonresident license OSP 5452 for JCB Laboratories LLC, Wichita, KS, status Expired, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054015447 for JCB LABORATORIES, WICHITA, KS, status CHANGE OF OWNERSHIP, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0000728 for JCB LABORATORIES, WICHITA, KS, status INACTIVE, as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0000610 for JCB Laboratories, Wichita, KS, status Expired, license A9-0001381 for JCB Laboratories, WICHITA, KS, status Closed and license AA-0000033 for JCB Laboratories, WICHITA, KS, status Closed, as of Nov 10, 2026.

Has JCB Laboratories, LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (Sep 22, 2021) for JCB Laboratories, LLC. State board of pharmacy records for Kansas are not checked: the board’s website answers automated requests with a bot challenge, and this index does not work around blocks.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
JCB Laboratories, LLC
Location
Wichita, KS
Type as FDA labels it
503A
FDA’s note
Out of business
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Sep 22, 2021
FDA Data Dashboard inspections
3 inspections: 2 OAI, 1 VAI; 3 published Form 483s
Form 483 text on this page
1 Form 483, 5 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as JCB Laboratories, LLC, a 503A facility, with 1 dated action.

Document
Sep 22, 2021FMD-145 letterFMD-145 Letter Issued 09/22/2021Not linked by FDA

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists JCB Laboratories LLC, Wichita, KS (FEI number 3004839646), matched to this page by exact name, city and state. It lists 3 inspections: 2 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Sep 14, 2018Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30048396461069957
Dec 3, 2015Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3004839646958930
Feb 27, 2013Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3004839646818211

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 5 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jan 16, 2015 to Dec 3, 2015: 5 observations

Firm on the cover
JCB Laboratories LLC, 7335 W 33rd St N, Wichita, KS 67205-9368 5038
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
8050 Marsh all Drive, Suite 205, L enex a, KS 66 214, (913)
Matched to this page by
firm name, city and state on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, you have not validated all of the strength testing for your finished pharmaceutical products.

Observation 2

The master production and control records are deficient in that they do not include complete manufacturing and instructions and testing.

Specifically, your Betamethasone Sodium Phosphate Injectable 6 mg/ml solution batch records do not specify if an <Redacted b4> can be used to <Redacted b4> in step <Redacted b4> of their batch record. You also do not record the amount of <Redacted b4>. In addition, you do not follow step <Redacted b4> of this manufacturing procedure. The procedure says you will <Redacted b4> the vials. Lastly, you do not record check fill volumes prior to using the <Redacted b4> in the aseptic filling process.

Specifically, for Lidocaine Jelly a.k.a. Tropicamide 0.2% I Cyclopentolate 0.2% I Phenylephrine 0.5% / Ketorolac 0.1% I Lidocaine Jelly 0.4%, the batch record does not contain adequate detailed instructions on how to mix the product. For example in step of your production record, it says to <Redacted b4>. There is no time requirement and there are no instructions on how to <Redaction b4>. In addition, the procedure does not record when your employees perform check fill volumes prior to filling product. ...

Read the full 483 (PDF on fda.gov)

Observation 3

There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, for DEV-20 15-306, discovered on 8112/20 15, you documented that you had no CAP A action planned for your latest sub-potent batch of product, except that you will continue to monitor all batch failures and note any trends. You identified "Potential human error." as a possible cause; however, there is no justification for this reason recorded in the deviation report. In addition, you did not identify or discuss that this manufacturing method is not validated, nor is the strength testing method validated. In fact, no root cause was identified, nor a CAPA initiated to try and prevent the problem from occurring again. 1bis product, Lidocaine JeJJy a.k .a Tropicamide 0.2% I Cyclopentolate 0.2% IPhenylephrine 0.5% IKetorolac 0.1% ILidocaine Jelly 0.4%, has had 5batches (140827@31 , 141118@ 12, 150305@6, 150312@1, and 150811@7) with sub-potency testing on the various API's found in this product postproduction. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

Th e location of the settling plates is inadequate to monitor the filling of the sterile product or the <R

edacted b4>, becau se are unable to indicate whether any viable organisms we re released over the product during the <Redacted b4>.

Specifically, in your Environmental Monitoring (EM), you monitor the < Redacted b4>, wher e your aseptic filling takes p

lace. The setting plates for EM <Redacted b4> are placed <Redacted b4> to the filling area where product is filled <Redacted b4>.

• You do not document that you perform EM sampling in all appropriate locations.

In the <Redacted b4> you perfo rm surface sampling <Redact ed b4> plates) in multiple areas; however, you do not docum ent that you perform surface sampling-plates) on <Redacted b4> within this <Redacted b4>.

First, you have <Redact ed b4> located in t he <Redacted b4> but <Redacted b4> is listed on the EM schedule and no records exist showing the monitoring of the other <Redacted b4>. These are dir ect ly behind the employees perform ing <Redacted b4> sterile filling. ...

Read the full 483 (PDF on fda.gov)

Observation 5

The container labels ofyour outsourcing facility?s drug products are deficient.

Specifically, the outer container packaging lacks route of administration for the following pharmaceuticals:

Epinephrine 1 :1000 1 mg/mL; Lidocaine HCL 4%, Epinephrine 0.05%, Tetracaine HCL 0.5% Topical 3 ml; Lidocaine HCL 1%, Phenylephrine HCL 1.5% 1 ml single use syringe; Tropicamide 1%, Cyclopentolate 1%, Phenylephrine 2.5%, Ketorolac 0.5% 0.5 mL single use syringe; Bevacizumab (Avastin) 2.5 mg/0.1mL single dose injection

For example the outer packaging for Epinephrine 1:1000 1 mg/mL is shipped in an opaque blue bag. You are unable to read the inner labeling, which contains the name ofthe drug and how it is used.

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Kansas are not checked: the board’s website answers automated requests with a bot challenge, and this index does not work around blocks.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 5452OSPJCB Laboratories LLCWichita, KSExpired

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054015447LICENSED PHARMACYJCB LABORATORIESWICHITA, KSCHANGE OF OWNERSHIP

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0000728NONRESIDENT PHARMACYJCB LABORATORIESWICHITA, KSINACTIVE

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0000610Non Resident PharmacyJCB LaboratoriesWichita, KSExpired
A9-0001381Non Resident PharmacyJCB LaboratoriesWICHITA, KSClosed
AA-0000033Outsourcing Facility-PharmacyJCB LaboratoriesWICHITA, KSClosed

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 2 products naming semaglutide under the labeler name “Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories”, matched to this pharmacy page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (2). The compounded product reports cover FDA reporting periods 2024-2 to 2025-1.

FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.

Reporting periods
71266-6100SemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
71266-6110SemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.